Drug Profile


Alternative Names: Arasertaconazole nitrate

Latest Information Update: 15 Jan 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ferrer
  • Class Antifungals
  • Mechanism of Action Sterol demethylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Vulvovaginal candidiasis

Most Recent Events

  • 15 Jan 2016 Ferrer plans a phase III trial for Vulvovaginal candidiasis in Spain (Ferrer pipeline, January 2016)
  • 14 Dec 2015 Arasertaconazole is ready to enter phase III development for vulvovaginal candidiasis
  • 13 May 2013 Arasertaconazole is available for licensing as of 08 May 2013.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top